Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q2FY26 results Revenue from Operations was Rs 974 crore for Q2FY26. EBIDTA margins for Q2FY26 stood at 34.4%, growth 250 bps. Profit After Tax (PAT) was Rs 255 crore for Q2FY26. Bhushan Akshikar, Managing Director, GSK India, said: “Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care. Moving ahead, we remain focused on ensuring that cutting-edge innovative treatments are both available and accessible to those who need them the most, supported by our comprehensive patient support and financing initiatives.” Result PDF
Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q1FY26 results Revenue from Operations stood at Rs 805 crore. Profit After Tax (PAT) of Rs 205 crore. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals, said: “GSK continues to invest in its innovative portfolio and is on track to launch the much-awaited oncology assets, Jemperli and Zejula. By launching these assets in India, GSK is addressing a critical unmet need amid a rising cancer burden and limited access to advanced therapies.” Jemperli (dostarlimab) is an immuno-oncology treatment for second-line dMMR endometrial cancer and Zejula (niraparib), is a PARP inhibitor indicated for advanced and recurrent ovarian cancer. Result PDF